For the month ended 30 April 2026, WuXi Biologics (Cayman) Inc. (WUXI BIO) reported a net issuance of 3.03 million ordinary shares, all arising from exercises under its Pre-IPO Share Option Scheme.

The newly issued shares lifted total outstanding shares (excluding treasury stock) to 4.14 billion, up from 4.14 billion a month earlier. No treasury shares were held or cancelled during the period, and the company confirmed that it continued to meet the Hong Kong Stock Exchange’s minimum 15% public-float requirement.

Option activity was concentrated in three Pre-IPO tranches granted between August 2016 and March 2017. Aggregate cash proceeds from these exercises amounted to USD 1.01 million. Following the exercises, 28.91 million options remain outstanding under the four active Pre-IPO tranches.

Authorised share capital was unchanged at 6.00 billion shares with a par value of USD 0.000008333333 each, representing total authorised capital of USD 50,000.

Beyond the option pool, the board-approved Restricted Share Award Scheme and the Global Partner Program together allow for a further 98.50 million ordinary shares to be issued in future periods; no shares were issued under these schemes in April.

With no new warrants, convertibles or treasury share movements reported, WUXI BIO’s latest filing underscores disciplined capital management while maintaining compliance with listing regulations.